Table 2. Health benefits of probiotic bacteria and their proposed mechanisms.
Health benefits | Proposed mechanism |
---|---|
Resistance to enteric pathogens | Antagonism |
Increased antibody production | |
Colonization resistance | |
Limiting access of enteric pathogens (pH, bacteriocins, antimicrobial peptides, lactic acid production) | |
Aid in lactose metabolism | Bacterial lactase hydrolyzes lactose in the small intestine |
Small bowel bacterial overgrowth | Decrease toxic metabolite production |
Normalize small bowel flora | |
Antibacterial characteristics | |
Immune system modulation | Strengthening of non-specific and antigen-specific defense |
Regulate/influence Th1/Th2 cell activation | |
Production of anti-inflammatory cytokines | |
Anticolon cancer effect | Antimutagenic and anticarcinogenic activity |
Detoxification of carcinogenic metabolites | |
Stimulation of immune function | |
Decreased detoxification/excretion of toxic microbial metabolites | Increased bifidobacterial cell counts and shift from a preferable protein-to carbohydrate-metabolizing microbial community |
Anti-Allergic activity (eczema or atopic dermatitis, asthma) | Prevention of antigen translocation into blood stream |
Prevent excessive immunologic responses to increased amount of antigen | |
Blood lipids, heart disease | Assimilation of cholestrol by bacterial cell |
Alteration in the activity of bile salt hydrolase (BSH) | |
Urogenital infections | Adhesion to urinary and vaginal tract cells |
Competitive exclusion | |
Necrotizing enterocolitis | Decrease in TLRs and signaling molecules and increase in negative regulations |
Reduction in IL-8 response | |
Rotavirus gastroenteritis | Increased IgA response to the virus |
Inflammatory bowel disease | Enhancement of mucosal barrier function |
Crohn disease | Reduction in proinflammatory cytokines production |
Adapted from Nagpal et al.23